Dallas, TXNCT07543991Now EnrollingIRB Ready

Giant Axonal Neuropathy (GAN) Clinical Trial in Dallas, TX

Access cutting-edge giant axonal neuropathy (gan) treatment through this clinical trial at a research site in Dallas. Study-provided care at no cost to qualified participants.

Sponsored by University of Texas Southwestern Medical Center

Quick Self-Assessment

See if you qualify for this Dallas location

Preparing your pre-screening questions…

Expert Care in Dallas

Access giant axonal neuropathy (gan) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related giant axonal neuropathy (gan) treatment provided free

Apply for This Dallas Location

Check if you qualify for this giant axonal neuropathy (gan) clinical trial in Dallas, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Dallas

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Dallas site if eligible
  4. 4Begin participation

About This Giant Axonal Neuropathy (GAN) Study in Dallas

Giant axonal neuropathy (GAN) is a rare pediatric disorder caused by autosomal recessive mutations in the GAN gene. GAN is a multisystem, neurodegenerative disorder affecting the peripheral nervous system (PNS), central nervous system (CNS) and autonomic nervous system (ANS). GAN is a fatal disease with many patients not surviving past early adulthood due to aspiration pneumonia and pulmonary complications. Currently, there are no approved drugs or other therapies for the treatment of GAN; and only supportive care therapies exist, leaving an unmet medical need to treat this rare, progressive, and ultimately fatal neurodegenerative disease. The drug used in this study (scAAV9/JeT-GAN) has been studied in a previous gene therapy clinical trial by which the drug was administered as a single injection into the spinal canal (intrathecal \[IT\] administration) to treat the symptoms associated with the CNS and PNS neurodegeneration; however, this administration method did not address the symptoms associated with neurodegeneration of the ANS. To treat the symptoms associated with ANS, this study has been designed to evaluate the safety and tolerability of a single dose of scAAV9/JeT-GAN administered directly into the left vagus nerve (intraneurally) in participants who have previously received scAAV9/JeT-GAN administered intrathecally. This study involves the use of an investigational drug called scAAV9/JeT-GAN "Investigational" means that the drug has not been approved by the U.S. Food \& Drug Administration (FDA) for the treatment of GAN and the progression of neurodegeneration to the CNS, PNS and ANS. This is the first study in humans to administer the drug directly into the left vagus nerve. We want to find out what effects, good and/or bad, scAAV9/JeT-GAN has when administered directly into the vagus nerve. The safety of intrathecal (IT) administration of scAAV9/JeT-GAN has been established in a prior research study; however, the people in this study will be the first people to receive the drug intraneurally. As a result, information about the safety and effectiveness of the route of administration is incomplete and all of the possible side effects are not yet known.

Sponsor: University of Texas Southwestern Medical Center

Who Can Participate

Inclusion Criteria

Confirmed diagnosis of GAN disease by:
Genomic DNA mutation analysis demonstrating homozygous or compound heterozygous, pathogenic and/or confirmed pathogenic variants in the GAN gene;
Clinical history or symptoms to ANS dysfunction.
Previously treated with IT AAV/GAN and completion of 5 year follow up prior to enrollment.
Parents/l LAR willing to accompany the participant to all study visits and who will provide consent for their child's participation.
Subject able to comply with all protocol requirements and procedures.
Up to date on childhood vaccinations according to Centers for Disease Control (CDC) guidelines. Annual influenza and COVID-19 vaccinations are highly recommended.
Female participants of child-bearing potential must have a negative urine and/or negative serum pregnancy test at screening/baseline; (a) Female participants must agree to use an effective form of birth control during study participation.

Exclusion Criteria

Inability to participate in study procedures (as determined by the site investigator).
Inability to be safely sedated in the opinion of the clinical anesthesiologist.
Concomitant illness or requirement for chronic drug treatment that in the opinion of the Principal Investigator (PI) creates unnecessary risks for gene transfer.
The presence of significant non-GAN related CNS impairment or behavioral disturbances that would confound the scientific rigor or interpretation of results of the study.
Have received an investigational drug within 30 days prior to screening or plan to receive an investigational drug (other than this gene therapy) during the study.
Currently participating in another interventional (drug/device) clinical trial.
Experienced an SAE (serious adverse event) related to scAAV9/JeT-GAN while participating in the first GAN IT study.
Contraindication to scAAV9/JeT-GAN or any of its ingredients.
Contraindication to any of the immune suppression medications used in this study.
Clinically significant abnormal laboratory values (GGT, ALT, and AST, or total bilirubin \> 3 × ULN, creatinine ≥ 1.5 mg/dL, hemoglobin \[Hgb\] \< 6 or \> 20 g/dL; white blood cell \[WBC\] \> 20,000 per cmm) prior to gene replacement therapy

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Dallas?

Yes, this clinical trial (NCT07543991) has an active research site in Dallas, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Giant Axonal Neuropathy (GAN) Treatment Options in Dallas, TX

If you're searching for giant axonal neuropathy (gan) treatment options in Dallas, TX, this clinical trial (NCT07543991) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Dallas research site is actively enrolling participants for this clinical trial. You'll receive care from experienced giant axonal neuropathy (gan) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all giant axonal neuropathy (gan) clinical trials near you to find additional studies recruiting in your area.

More Neuropathy Trials in Dallas, TX

See all neuropathy clinical trials recruiting in Dallas — not just this study.

Browse Neuropathy Trials in Dallas

Ready to Join in Dallas?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Dallas, TX